ProMIS Neurosci (PMN) Receives a Buy from Noble Financial

By Carrie Williams

A Wall Street analyst has provided a review for the Healthcare company today, but retained the same rating on the stock. Analyst Cosme Ordonez from Noble Financial remains bullish on ProMIS Neurosci (PMNResearch Report) and has a C$1 price target.

According to TipRanks.com, Ordonez is ranked #3516 out of 5181 analysts.

ProMIS Neurosci has an analyst consensus of Hold.

Based on ProMIS Neurosci’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of C$2.45 million. In comparison, last year the company had a GAAP net loss of C$1.56 million.

ProMIS Neurosciences, Inc. operates as a development stage biotech company. It discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and amyotrophic lateral sclerosis.

The company’s shares closed on Tuesday at C$0.26.